CAS: 2363-58-8; Epitiostanol

该化合物是一种由睾丸酮衍生的合成代谢类类固醇,其特点是其独特的结构改变,它增强了其代谢特性,同时减少和诱因效应;该化合物以其能够促进肌肉生长和提高体能性能而闻名,使其在医疗和体育环境中都引起兴趣;该化合物具有很强的亲和性和受色素感应体,有助于其代谢效应;该物质一般是口服的,与其他代谢类固醇相比,其毒性特征相对较低;然而,它与其他许多类固醇一样,可导致各种副作用,包括荷尔蒙不平衡和潜在肝毒性,而且使用时间很长;由于其代谢特性,乙基stanol在竞争性体育中被禁止,其用途在许多国家受到管制;其药理学影响研究仍在继续,特别是在肌肉消亡条件下的潜在治疗用途.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-12391691-B2
      优先权日:2018-11-16
      标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
      发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
      权利人:AMGEN INC
      摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

      专利号:US-2025206736-A1
      优先权日:2019-11-14
      标题 :Synthesis of kras g12c inhibitor compound
      发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
      权利人:AMGEN INC
      摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

      专利号:WO-2017100796-A1
      优先权日:2015-12-11
      标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
      发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
      权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
      摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

      专利号:US-2017283878-A1
      优先权日:2015-12-11
      标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
      发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
      权利人:ACADEMIA SINICA
      摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

      专利号:US-10342858-B2
      优先权日:2015-01-24
      标题 :Glycan conjugates and methods of use thereof
      发明人:WONG CHI-HUEY; WU CHUNG-YI
      权利人:ACADEMIA SINICA
      摘要:The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
      台州百大药业有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.chinahormone.com
      电话: 0086-571-85215532/18167103925👤
      📞台州百大药业有限公司 ⚠️参考联系方式

      销售电话:0086-571-85215532/18167103925
      邮箱: taifa@chinahormone.com
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      合成参考文献


      摘要:Kiso to Rinsho. Clinical Report., 7(2983), 1973
      参考文献:10.1093/oxfordjournals.jbchem.a121720
      摘要:Ueda H, Hagino Y, Ono M, Kuwano M. Human mammary cancer cell mutants with altered hormone receptor activity. J Biochem. 1986 Aug;100(2):341–8. doi: 10.1093/oxfordjournals.jbchem.a121720.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知